Enveric Biosciences (NASDAQ:ENVB) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Enveric Biosciences (NASDAQ:ENVB) announced its earnings results on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30, Yahoo Finance reports.

Enveric Biosciences Price Performance

Shares of ENVB traded down $0.04 on Wednesday, hitting $0.49. The company’s stock had a trading volume of 104,866 shares, compared to its average volume of 2,381,502. The company has a market capitalization of $3.90 million, a PE ratio of -0.08 and a beta of 0.74. Enveric Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $2.92. The company has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.83.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.